07:00 , Aug 2, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Cerebral cavernous malformation 2 (CCM2); serine/threonine kinase 25 (STK25) In vitro studies suggest increasing STK25 activity could help treat pediatric neural cancers. In human...
07:00 , Sep 8, 2011 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Inducible mouse models of cerebral cavernous malformations (CCM) Inducible mouse models of CCM could aid the development of new treatments for vascular hemorrhages caused by...
07:00 , Jul 22, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Rheumatoid arthritis (RA) NK cells Studies in patient-derived cells and in mice suggest that depleting NK cells in arthritic joints could help treat RA....
07:00 , Jul 22, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Cerebral cavernous malformation (CCM) KRIT1 ankyrin repeat containing (KRIT1; CCM1); cerebral cavernous malformation 2 (CCM2); programmed cell death 10 (PDCD10; CCM3) In vitro and...
07:00 , Sep 17, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Brain cancer Cerebral cavernous malformation 2 (CCM2); neurotrophic tyrosine kinase receptor 1 (NTRK1;TrkA) In vitro studies suggest that upregulating CCM2 could help treat neuroblastoma....
08:00 , Jan 29, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Cerebral cavernous malformation (CCM); vascular dysplasia Cerebral cavernous malformation 2 (CCM2); ras homolog gene family, member A (RHOA); HMG-CoA reductase...